A new arylbenzofuran derivative functions as an anti-tumour agent by inducing DNA damage and inhibiting PARP activity

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Hongbo ^a   Zeng, Xiaobin ^a,b   Gao, Chunmei ^a   Ming, Pinghong ^c   Zhang, Jianping ^d   Guo, Caiping ^d   Zhou, Lanzhen ^d   Lu, Yin ^e   Wang, Lijun ^a   Huang, Laiqiang ^a   He, Xiangjiu ^f   Mei, Lin ^a  

^a TSINGHUA UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c ZHUHAI PEOPLE S HOSPITAL ZHUHAI HOSPITAL AFFILIATED WITH JINAN UNIVERSITY   (China)

^d Shenzhen Weiwuguangming Biological Products Co Ltd   (China)

^e SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^f GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOFURAN DERIVATIVE; CYCLIN A2; CYCLIN DEPENDENT KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN BINDING;

APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; CONFORMATION; DNA DAMAGE; DNA REPAIR; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZOFURANS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A2; CYCLIN-DEPENDENT KINASE 2; DNA DAMAGE; DNA REPAIR; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84930652409     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10893     Document Type: Article

References (55)

1. Kane M. A., Serrano B., de Sanjose S. & Wittet S. Implementation of human papillomavirus immunization in the developing world. Vacc. 30 (Suppl 5), F192-200 (2012
2. Iwasawa A., Nieminen P., Lehtinen M. & Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Canc. 77, 2275-2279 (1996
3. Wheeler C. M., et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J. Natl. Canc. Inst. 101, 475-487 (2009
4. Jiang P. & Yue Y. Human papillomavirus oncoproteins and apoptosis. Exp. Ther. Med. 7, 3-7 (2014
5. Paavonen J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lanc. 13, 301-314 (2009
6. Brown D. R., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199, 926-935 (2009
7. Wheeler C. M., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lanc. Oncol. 13, 100-110 (2012
8. Hakim A. A. & Dinh T. A. Worldwide impact of the human papillomavirus vaccine. Curr. Treat. Opt. Oncol. 10, 44-53 (2009
9. Elit L. M. & Hirte H. Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert. Rev. Anticanc. Ther. 14, 319-332 (2014
10. Crisp M. D., Isagi Y., Kato Y., Cook L. G. & Bowman D. M. Livistona palms in Australia: ancient relics or opportunistic immigrants?Mol. Phylogenet. Evol. 54, 512-523 (2010
11. Zhong Z. G., Zhang F. F., Zhang W. Y. & Cui J. G. Study on the anticancer effects of extracts from roots of Livistona chinensis in vitro. Zhong. Yao. Cai. 30, 60-63 (2007
12. Wang H., Li A., Dong X. P. & Xu X. Y. Screening of anti-tumor parts from the seeds of Livistona chinensis and its antiangiogenesis effect. Zhong. Yao. Cai. 31, 718-722 (2008
13. Zeng X., et al. Bioactive phenolics from the fruits of Livistona chinensis. Fitoterapia. 83, 104-109 (2012
14. Fleischer A., et al. Modulating apoptosis as a target for effective therapy. Mol Immunol. 43, 1065-1079 (2006
15. Kim R., Emi M., & Tanabe K. Role of mitochondria as the gardens of cell death. Cancer. Chemother. Pharmacol. 57, 545-553 (2006
16. Zhou B. B. & Elledge S. J. The DNA damage response: putting checkpoints in perspective. Nat. 408, 433-439 (2000
17. Wang J., et al. ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J. Biol. Chem. 279, 39584-39592 (2004
18. Tyagi A., et al. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinog. 26, 1978-1987 (2005
19. Jackson S. P. DNA damage detection by DNA dependent protein kinase and related enzymes. Canc. Surv. 28, 261-279 (1996
20. Durocher D. & Jackson S. P. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?. Curr. Opin. Cell. Biol. 13, 225-231 (2001
21. Yang J., Yu Y., Hamrick H. E. & Duerksen-Hughes P. J. ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinog. 24, 1571-1580 (2003
22. Shiloh Y. & Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell. Biol. 14, 197-210 (2013
23. Falck J., Coates J. & Jackson S. P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nat. 434, 605-611 (2005
24. Hollick J. J., et al. 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK). Bioorg. Med. Chem. Lett. 13, 3083-3086 (2003
25. Dejmek J., Iglehart J. D. & Lazaro J. B. DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol. Canc. Res. 7, 581-591 (2009
26. Wang H., et al. CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBVpositive hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 422, 103-108 (2012
27. Satoh M. S. & Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nat. 356, 356-358 (1992
28. Wang Z., Wang F., Tang T. & Guo C. The role of PARP1 in the DNA damage response and its application in tumor therapy. Front. Med. 6, 156-164 (2012
29. Thomas C. & Tulin A. V. Poly-ADP-ribose polymerase: machinery for nuclear processes. Mol. Aspects. Med. 34, 1124-1137 (2013
30. de Murcia G., et al. Structure and function of poly(ADP-ribose) polymerase. Mol. Cell. Biochem. 138, 15-24 (1994
31. Kinoshita T., et al. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS. Lett. 556, 43-46 (2004
32. Langelier M. F., Planck J. L., Roy S. & Pascal J. M. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Sci. 336, 728-732 (2012
33. Bryant H. E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434, 913-917 (2005
34. Farmer H., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917-921 (2005
35. McCabe N., et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer. Biol. Ther. 4, 934-936 (2005
36. Meikrantz W., Gisselbrecht S., Tam S. W. & Schlegel R. Activation of cyclin A-dependent protein kinases during apoptosis. Proc. Natl. Acad. Sci. USA. 91, 3754-3758 (1994
37. Gil-Gomez G., Berns A. & Brady H. J. A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO. J. 17, 7209-7218 (1998
38. Adachi S., et al. Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. Circ. Res. 88, 408-414 (2001
39. Yin H., Subrata S., Yang W. & Yang G. Overexpression of cyclin A leads to S-phase arrested apoptosis. Hua Xi Yi Ke Da Xue Xue Bao 32, 188-190 (2001
40. Ding H., et al. OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis. Int. J. Canc. 123, 2923-2930 (2008
41. Heitz F., et al. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert. Rev. Anticanc. Ther. 10, 1125-1136 (2010
42. Cipak L. & Jantova S. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy. Neoplasma 57, 401-405 (2010
43. Glendenning J. & Tutt A. PARP inhibitors-current status and the walk towards early breast cancer. Breast 20 (Suppl 3), S12-19 (2011
44. Le Rhun Y., Kirkland J. B. & Shah G. M. Cellular responses to DNA damage in the absence of Poly(ADP-ribose) polymerase. Biochem. Biophys. Res. Commun. 245, 1-10 (1998
45. Jagtap P. & Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug. Discov. 4, 421-440 (2005
46. Smith L. M., Willmore E., Austin C. A. & Curtin N. J. The novel poly(ADP-ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin.Canc. Res. 11, 8449-8457 (2005
47. Cepeda V., et al. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Rec. Pat. Anticanc. Drug. Discov. 1, 39-53 (2006
48. Heacock M. L., Stefanick D. F., Horton J. K. & Wilson S. H. Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. DNA Repair (Amst) 9, 929-936 (2010
49. Cheng H., et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinog. 34, 739-749 (2013
50. Minami D., et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol. Canc. Res. 11, 140-148 (2013
51. Lord C. J., McDonald S., Swift S., Turner N. C. & Ashworth A. A. high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 7, 2010-2019 (2008
52. Turner N. C., et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO. J. 27, 1368-1377 (2008
53. Williamson C. T., et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol. Canc. Ther. 9, 347-357 (2010
54. Weston V. J., et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116, 4578-4587 (2010
55. Wang X., Song Y., Ren J. & Qu X. Knocking-down cyclin A(2) by siRNA suppresses apoptosis and switches differentiation pathways in K562 cells upon administration with doxorubicin. PLoS One 4, e6665 (2009